Biologics for treating axial spondyloarthritis

Alexis Jones, Coziana Ciurtin, Mediola Ismajli, Maria Leandro, Raj Sengupta, Pedro M Machado

Research output: Contribution to journalReview article

Abstract

INTRODUCTION: Spondyloarthritis (SpA) encompasses a heterogeneous group of diseases sharing genetic, immunological, clinical and imaging features. Axial spondyloarthritis (axSpA) refers to a subgroup characterised predominately by inflammation of the axial skeleton with subsequent symptoms of chronic (often inflammatory) back pain and sacroiliitis. There is a strong association with the major histocompatibility complex (MHC) class I allele human leukocyte antigen (HLA) B27. In the last decade, there has been significant progress in earlier detection of the disease and the molecular mechanisms involved in its pathogenesis. The subsequent introduction of anti-tumour necrosis factor (TNF) has revolutionised the treatment of patients with axSpA. Areas covered: In this article, we review the current biologic therapies for axSpA, the emergence of biosimilars, predictors of response, primary and secondary failure and new biologics on the horizon. Expert opinion: There have been significant advances in the treatment of axSpA. Beyond the clear efficacy of anti-TNF inhibition, IL-17 offers an alternative therapeutic target and there is promise from inhibition of the IL-17/IL-23 pathway and small molecules, such as Janus kinase (JAK) inhibitors. Biosimilars have offered greater affordability and choice within this increasingly growing field of therapeutics.

Original languageEnglish
Pages (from-to)641-652
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume18
Issue number6
Early online date7 May 2018
DOIs
Publication statusPublished - 2018

Fingerprint

Biosimilar Pharmaceuticals
Interleukin-17
Biological Products
Tumor Necrosis Factor-alpha
Janus Kinases
Interleukin-23
HLA Antigens
Sacroiliitis
Imaging techniques
Inborn Genetic Diseases
Biological Therapy
Molecules
Expert Testimony
Therapeutics
Back Pain
Major Histocompatibility Complex
Skeleton
Early Diagnosis
Alleles
Inflammation

Keywords

  • ankylosing spondylitis
  • anti-IL17
  • anti-TNF
  • biologics
  • biosimilars
  • Spondyloarthritis

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Jones, A., Ciurtin, C., Ismajli, M., Leandro, M., Sengupta, R., & Machado, P. M. (2018). Biologics for treating axial spondyloarthritis. Expert Opinion on Biological Therapy, 18(6), 641-652. https://doi.org/10.1080/14712598.2018.1468884

Biologics for treating axial spondyloarthritis. / Jones, Alexis; Ciurtin, Coziana; Ismajli, Mediola; Leandro, Maria; Sengupta, Raj; Machado, Pedro M.

In: Expert Opinion on Biological Therapy, Vol. 18, No. 6, 2018, p. 641-652.

Research output: Contribution to journalReview article

Jones, A, Ciurtin, C, Ismajli, M, Leandro, M, Sengupta, R & Machado, PM 2018, 'Biologics for treating axial spondyloarthritis', Expert Opinion on Biological Therapy, vol. 18, no. 6, pp. 641-652. https://doi.org/10.1080/14712598.2018.1468884
Jones, Alexis ; Ciurtin, Coziana ; Ismajli, Mediola ; Leandro, Maria ; Sengupta, Raj ; Machado, Pedro M. / Biologics for treating axial spondyloarthritis. In: Expert Opinion on Biological Therapy. 2018 ; Vol. 18, No. 6. pp. 641-652.
@article{5e8da40e25e24d73ab36727497382d7c,
title = "Biologics for treating axial spondyloarthritis",
abstract = "INTRODUCTION: Spondyloarthritis (SpA) encompasses a heterogeneous group of diseases sharing genetic, immunological, clinical and imaging features. Axial spondyloarthritis (axSpA) refers to a subgroup characterised predominately by inflammation of the axial skeleton with subsequent symptoms of chronic (often inflammatory) back pain and sacroiliitis. There is a strong association with the major histocompatibility complex (MHC) class I allele human leukocyte antigen (HLA) B27. In the last decade, there has been significant progress in earlier detection of the disease and the molecular mechanisms involved in its pathogenesis. The subsequent introduction of anti-tumour necrosis factor (TNF) has revolutionised the treatment of patients with axSpA. Areas covered: In this article, we review the current biologic therapies for axSpA, the emergence of biosimilars, predictors of response, primary and secondary failure and new biologics on the horizon. Expert opinion: There have been significant advances in the treatment of axSpA. Beyond the clear efficacy of anti-TNF inhibition, IL-17 offers an alternative therapeutic target and there is promise from inhibition of the IL-17/IL-23 pathway and small molecules, such as Janus kinase (JAK) inhibitors. Biosimilars have offered greater affordability and choice within this increasingly growing field of therapeutics.",
keywords = "ankylosing spondylitis, anti-IL17, anti-TNF, biologics, biosimilars, Spondyloarthritis",
author = "Alexis Jones and Coziana Ciurtin and Mediola Ismajli and Maria Leandro and Raj Sengupta and Machado, {Pedro M}",
year = "2018",
doi = "10.1080/14712598.2018.1468884",
language = "English",
volume = "18",
pages = "641--652",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Biologics for treating axial spondyloarthritis

AU - Jones, Alexis

AU - Ciurtin, Coziana

AU - Ismajli, Mediola

AU - Leandro, Maria

AU - Sengupta, Raj

AU - Machado, Pedro M

PY - 2018

Y1 - 2018

N2 - INTRODUCTION: Spondyloarthritis (SpA) encompasses a heterogeneous group of diseases sharing genetic, immunological, clinical and imaging features. Axial spondyloarthritis (axSpA) refers to a subgroup characterised predominately by inflammation of the axial skeleton with subsequent symptoms of chronic (often inflammatory) back pain and sacroiliitis. There is a strong association with the major histocompatibility complex (MHC) class I allele human leukocyte antigen (HLA) B27. In the last decade, there has been significant progress in earlier detection of the disease and the molecular mechanisms involved in its pathogenesis. The subsequent introduction of anti-tumour necrosis factor (TNF) has revolutionised the treatment of patients with axSpA. Areas covered: In this article, we review the current biologic therapies for axSpA, the emergence of biosimilars, predictors of response, primary and secondary failure and new biologics on the horizon. Expert opinion: There have been significant advances in the treatment of axSpA. Beyond the clear efficacy of anti-TNF inhibition, IL-17 offers an alternative therapeutic target and there is promise from inhibition of the IL-17/IL-23 pathway and small molecules, such as Janus kinase (JAK) inhibitors. Biosimilars have offered greater affordability and choice within this increasingly growing field of therapeutics.

AB - INTRODUCTION: Spondyloarthritis (SpA) encompasses a heterogeneous group of diseases sharing genetic, immunological, clinical and imaging features. Axial spondyloarthritis (axSpA) refers to a subgroup characterised predominately by inflammation of the axial skeleton with subsequent symptoms of chronic (often inflammatory) back pain and sacroiliitis. There is a strong association with the major histocompatibility complex (MHC) class I allele human leukocyte antigen (HLA) B27. In the last decade, there has been significant progress in earlier detection of the disease and the molecular mechanisms involved in its pathogenesis. The subsequent introduction of anti-tumour necrosis factor (TNF) has revolutionised the treatment of patients with axSpA. Areas covered: In this article, we review the current biologic therapies for axSpA, the emergence of biosimilars, predictors of response, primary and secondary failure and new biologics on the horizon. Expert opinion: There have been significant advances in the treatment of axSpA. Beyond the clear efficacy of anti-TNF inhibition, IL-17 offers an alternative therapeutic target and there is promise from inhibition of the IL-17/IL-23 pathway and small molecules, such as Janus kinase (JAK) inhibitors. Biosimilars have offered greater affordability and choice within this increasingly growing field of therapeutics.

KW - ankylosing spondylitis

KW - anti-IL17

KW - anti-TNF

KW - biologics

KW - biosimilars

KW - Spondyloarthritis

UR - http://www.scopus.com/inward/record.url?scp=85048271722&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1468884

DO - 10.1080/14712598.2018.1468884

M3 - Review article

VL - 18

SP - 641

EP - 652

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -